Skip to main content

Table 3 Sexual behaviors and their associations with KSHV infection and HSV-2 infection in study participants

From: Prevalence and correlates of Kaposi’s sarcoma-associated herpesvirus and herpes simplex virus type 2 infections among adults: evidence from the NHANES III data

Characteristic

All subjects, No (%)

KSHV

HSV-2

Infection, n/N (%)

OR (95% CI)

aORs$ (95% CI)

Infection, n/N (%)

OR (95% CI)

aORsF$ (95% CI)

Sexual

 No sex

344(2.98)

1.82

1.00

1.00

5.93

1.00

1.00

 Sex

11,185(97.20)

1.62

0.89

(0.40,2.52)

0.72

(0.31,2.06)

30.27

6.89*

(4.23,12.15)

4.64*

(2.82,8.26)

 P

  

0.796

0.532

 

 < 0.001*

 < 0.001*

Initial sexual age

 ≤ 18 years

8339(74.56)

1.74

1.00

1.00

32.39

1.00

1.00

 19–29

2776(24.82)

1.28

0.73

(0.48,1.08)

0.72

(0.47,1.08)

23.71

0.65*

(0.58,0.73)

0.56*

(0.49,0.64)

 ≥ 30

70(0.63)

1.72

0.99

(0.06,4.56)

0.81

(0.05,3.85)

25.00

0.70

(0.34,1.37)

0.47*

(0.22,0.93)

 P

  

0.154

0.083

 

 < 0.001*

 < 0.001*

Sex partners

 1

2418(21.91)

1.40

1.00

1.00

16.40

1.00

1.00

 2–4

3481(31.54)

1.61

1.15

(0.72,1.86)

1.13

(0.70,1.84)

30.26

2.21*

(1.90,2.58)

2.38*

(2.02,2.80)

 5–9

2249(20.38)

1.81

1.29

(0.78,2.15)

1.23

(0.72,2.09)

35.60

2.82*

(2.40,3.32)

3.48*

(2.91,4.18)

  ≥ 10

2890(26.18)

1.66

1.18

(0.73,1.95)

1.06

(0.61,1.84)

35.90

2.85*

(2.45,3.34)

4.85*

(4.03,5.85)

 P

  

0.463

0.574

 

 < 0.001*

 < 0.001*

The duration of sexual activity

 0–20

6243(54.15)

1.25

1.00

1.00

24.14

1.00

1.00

 21–30

2946(25.55)

2.07

1.67*

(1.15,2.40)

1.53

(0.90,2.58)

36.91

1.84*

(1.65,2.05)

1.47*

(1.25,1.72)

 31–40

1812(15.72)

1.95

1.57*

(1.00,2.42)

1.29

(0.58,2.81)

35.90

1.76*

(1.53,2.03)

1.83*

(1.43, 2.34)

  ≥ 40

528(4.58)

2.57

2.08*

(1.00,3.89)

1.58

(0.54,4.36)

40.53

2.14*

(1.66,2.76)

2.46*

(1.69,3.59)

 P

  

0.004*

0.320

 

 < 0.001*

0.002*

Sex partners in the past year

 0

1110(9.92)

2.62

1.00

1.00

32.30

1.00

1.00

 1

8188(73.20)

1.52

0.57*

(0.37,0.92)

0.62*

(0.40,1.01)

28.83

0.85

(0.72,1.00)

1.01

(0.84,1.21)

 2–4

1588(14.20)

1.37

0.52*

(0.28,0.95)

0.54

(0.28,1.01)

35.17

1.14

(0.94,1.38)

1.55*

(1.25,1.94)

 5–9

219(1.96)

2.84

1.09

(0.36,2.67)

1.08

(0.35,2.77)

33.33

1.05

(0.73,1.49)

1.78*

(1.20,2.60)

  ≥ 10

81(0.72)

–

–

–

41.27

1.47

(0.86,2.48)

2.07*

(1.17,3.64)

 P

  

0.132

0.205

 

0.002*

 < 0.001*

Sexual preference

 No-MSM

 4922(98.34)

1.63

1.00

1.00

22.30

1.00

1.00

 MSM

83(1.66)

7.25

4.71*

(1.61,11.03)

4.98*

(1.69,11.77)

39.68

2.29*

(1.36,3.80)

2.85*

(1.65,4.87)

 P

  

0.001*

 < 0.001*

 

0.001*

 < 0.001*

  1. KSHV Kaposi’s sarcoma-associated herpesvirus, the KSHV seroprevalence was used antibodies to K8.1; OR Odds ratio; aORs adjusted odds ratios; CI confidence interval
  2. *Statistically significant association
  3. $OR and 95%CI adjusted for age, sex and race/ethnicity as shown in Table 1
Back to article page

Virology Journal

ISSN: 1743-422X